Anthony Mato, MD

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting.

Circumstances for which MRD testing may be considered for patients with chronic lymphocytic leukemia.

Considerations for using novel fixed-duration regimens and triplet therapy to treat patients with chronic lymphocytic leukemia.

Anthony Mato, MD, MSCE, discusses the potential utilization of CAR T-cell therapy in earlier lines of therapy in chronic lymphocytic leukemia.

Anthony Mato, MD, MSCE, discusses recent advances made in the treatment of patients with chronic lymphocytic leukemia.

Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).